Coronavirus Update: China Firms Form mRNA Vaccine JV
India, UK Resolve Travel Issues
Executive Summary
Two Chinese firms join forces to develop mRNA vaccines; UK and India resolve issues over the travel of vaccinated individuals; and Scrip speaks to the CEO of a Canadian firm developing mRNA vaccines.
You may also be interested in...
Recbio First Biotech To Brave A Hong Kong IPO In 2022
Chinese vaccine maker Recbio hopes an IPO in Hong Kong will bring investor attention to its mRNA COVID vaccine with potential against the Omicron variant.
China’s Lead mRNA COVID-19 Vaccine Candidate Faces Phase III Delays
The leader in China's homegrown mRNA COVID-19 vaccine effort expects a delay to key Phase III results, with analysts now expecting to see figures from the international portion of the study in early 2022.
UK Travel Rule Sparks Row As India Seeks To Resume COVID-19 Vaccine Diplomacy
As India gets set to resume COVID-19 vaccine diplomacy from October, a new rule which will require Indians visiting UK who are fully vaccinated with AstraZeneca partner Serum Institute’s vaccine to undergo quarantine has sparked a row. Meanwhile, Indian companies await a nod from the WHO for wider acceptance of their COVID-19 vaccines.